Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27793130 | 0.98 | EPHX2 (0.33) | EPHX2 | |
| SCHEMBL29087328 | 0.79 | TSHR (0.46) | EPHX2 | |
| SCHEMBL491105 | 0.78 | EPHX2 (0.32) | EPHX2 | |
| SCHEMBL3447711 | 0.78 | TSHR (0.44) | EPHX2 | |
| SCHEMBL2503186 | 0.77 | CYP2C19 (0.40) | EPHX2 | |
| SCHEMBL5823235 | 0.76 | CYP2C19 (0.43) | EPHX2 | |
| SCHEMBL12358722 | 0.76 | EPHX2 (0.32) | EPHX2 | |
| SCHEMBL27960992 | 0.76 | TSHR (0.46) | EPHX2 | |
| SCHEMBL8098512 | 0.75 | EPHX2 (0.35) | EPHX2 | |
| SCHEMBL23833073 | 0.73 | EPHX2 (0.32) | EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8030489-B2 | Ornithine derivative | ASTELLAS PHARMA INC. (JP) | 2011-10-04 | — | — | US | disclosed |
| US-20100216803-A1 | ORNITHINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-08-26 | — | — | US | disclosed |
| EP-2141147-A1 | ORNITHINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2010-01-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216803-A1 | ORNITHINE DERIVATIVE | PTGER4, OXER1, ODC1 | EPHX2 120/4885HDAC3 2412/4885HDAC1 3656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.